Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by MrFraischeon Jun 03, 2020 12:13pm
70 Views
Post# 31106985

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:can we talk about potential numbers on the Logs in the Fire

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:can we talk about potential numbers on the Logs in the Fire

You honestly still don't understand? 

I didn't say they would lose less, I said they would lose very little more since the cancer testing brought in such a small amount of revenue. A 25% decrease of an already small number doesn't make much of a difference.

If they lost $2.7m with "50% capacity" (100% = $50k rev), that means that their losses WITH NO TESTING AT ALL would have been 2.7m + (0.5 * 50k) = $2.725m. But since they received 25k (50% of 50k) in revenue, their losses were $2.7m.

If they then have an additional decrease of capacity, so they only have 25%, that would mean that their revenue from the testing during that quarter would be (0.25 * 50k). So if you then assume that they would have had the same losses WITH NO TESTING AT ALL as in the previous quarter, their losses would be: $2.725 - (0.25 * 50k) = $2.7125

Please tell me you understand now.

Bullboard Posts